Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy
Oral Diseases · 10.11.2026
DOI: 10.1111/odi.70569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 10.11.2026. Verfasst von Weiman Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Oral Health Research, Hunan 3D Printing Engineering Research Center of Oral Care, Hunan Clinical Research Center of Oral Majo…. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Changsha, Hunan Provincial Graduate Research and Innovation Project, Innovation Project for Postgraduates of Central South University.
Abstract (Originalsprache)
Objectives
To investigate the anti‐fibrotic effects and mechanism of action of the bioactive peptide HX‐12C in oral submucous fibrosis. Materials and Methods Primary human buccal mucosal fibroblasts were treated with arecoline to induce a myofibroblast phenotype. The effects of HX‐12C on cell proliferation, migration and fibrotic markers were assessed. Molecular docking and immunofluorescence were used to examine HX‐12C binding to transforming growth factor‐beta receptor I, validated by the inhibitor SB‐431542. In vivo efficacy was evaluated in a bleomycin‐induced rat model of oral submucous fibrosis.
Results
HX‐12C promoted fibroblast proliferation and migration but suppressed arecoline‐induced myofibroblast activation, downregulating alpha‐smooth muscle actin, fibronectin and collagens I/III. Mechanistically, HX‐12C bound to transforming growth factor‐beta receptor I, inhibited SMAD2/3 phosphorylation and downstream pro‐fibrotic gene expression, effects attenuated by SB‐431542. In vivo, HX‐12C improved mouth opening and reduced collagen deposition.
Conclusions
HX‐12C exerts potent anti‐fibrotic effects by directly targeting transforming growth factor‐beta receptor I and inhibiting the canonical transforming growth factor‐beta/Smad signalling pathway. Our findings identify HX‐12C as a promising therapeutic candidate for oral submucous fibrosis and provide a rationale for developing peptide‐based therapies for transforming growth factor‐beta‐driven fibrotic diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hunan Key Laboratory of Oral Health Research, Hunan 3D Printing Engineering Research Center of Oral Care, Hunan Clinical Research Center of Oral Major Diseases and Oral Health, Xiangya Stomatological Hospital and Xiangy…
- Hunan Engineering Technology Research Center for Comprehensive Development and Utilization of Biomass Resources, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, Hunan, Chi…
Förderung
- Natural Science Foundation of Changsha
- Hunan Provincial Graduate Research and Innovation Project
- Innovation Project for Postgraduates of Central South University
Zitieren
APA
Huang, W., Shi, R., Wang, Y., Wang, X., Qin, Z., Luo, X., Li, K., Wang, B., & Hu, Y. (2026). Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy. Oral Diseases. https://doi.org/10.1111/odi.70569
Vancouver
Huang W, Shi R, Wang Y, Wang X, Qin Z, Luo X, et al. Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy. Oral Diseases. 2026. doi:10.1111/odi.70569
BibTeX
@article{Huang2026,
author = {Huang, Weiman and Shi, Rujie and Wang, Yujing and Wang, Xidi and Qin, Zuodong and Luo, Xiaofang and Li, Kun and Wang, Baisheng and Hu, Yanjia},
title = {Bioactive Peptide HX ‐ 12C Ameliorates Oral Submucous Fibrosis via Inhibition of TGF ‐β/Smad‐Driven Myofibroblast Activation: A Potential Therapeutic Strategy},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70569}
}
EUVIMED